By Finance Pulse in investment —

H.C. Wainwright Rates Nuvalent as a Buy with $110 Target

H.C. Wainwright initiates coverage on Nuvalent (NUVL) with a Buy rating and $110 price target, highlighting its potential in lung cancer treatment innovation.

Artistic representation of a financial graph with a focus on growth and innovation, symbolizing Nuva
H.C. Wainwright Rates Nuvalent as a Buy with $110 Target

H.C. Wainwright initiated Nuvalent (NUVL) with a Buy rating and $110 price target, citing potential in reshaping lung cancer treatment.

Source